Albany, NY -- (SBWIRE) -- 07/05/2019 -- Recurrent Pericarditis Market Insights, Epidemiology and Market Forecast-2028

5 July 2019

1. Acute pericarditis is found in approximately 5% of patients. It occurs most often in men of 20 to 50 years of age.
2. Acute pericarditis incidence was significantly higher for men than for women
3. The pericarditis accounts for 0.2% of all hospital cardiovascular admissions and is diagnosed in approximately 5% of patients with non-ischemic chest pain in emergency departments

(Albany, US) DelveInsight launched a new report on Recurrent Pericarditis Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Recurrent Pericarditis market report covers a descriptive overview and comprehensive insight of the Recurrent Pericarditis epidemiology and Recurrent Pericarditis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Recurrent Pericarditis market report provides insights on the current and emerging therapies.
3. Recurrent Pericarditis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Recurrent Pericarditis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Recurrent Pericarditis market.

Request for sample pages

"Recurrence rate after an initial episode of pericarditis ranges from 15 to 30%, and may increase to 50% after the first recurrence in patients not treated with colchicine, particularly if treated with corticosteroids."

Recurrent Pericarditis treatment can be successfully done in the outpatient setting. Clinical presentation, presumed aetiology, medical history, and response to previous treatments help in determining the management options. Patients at higher risk should be treated in the hospital.
First-line treatment includes nonsteroidal anti-inflammatory drugs and colchicine. Glucocorticoids are traditionally reserved for severe or refractory cases, or in cases when the cause of pericarditis is likely to be connective tissue disease, autoreactivity, or uremia. Cardiology consultation is recommended for patients with severe disease, those with pericarditis refractory to empiric treatment, and those with unclear etiologies.
Over the recent years, important steps have been taken towards an understanding of the Recurrent Pericarditis, and several potential the Recurrent Pericarditis therapeutic targets were also identified. Further progress in the research and development is likely to translate into a real improvement in Recurrent Pericarditis treatment options for patients and is likely to boost the revenue growth of Recurrent Pericarditis therapeutics market in the forecast period.

Players such as Kiniska Pharmaceuticals, involved in developing therapies for Recurrent Pericarditis, and launch of emerging therapies, such as Rilonacept (Kiniska Pharmaceuticals) is expected to significantly impact Recurrent Pericarditis treatment scenario in the upcoming years.

Table of contents

1. Report Introduction
2. Recurrent Pericarditis Market Overview at a Glance
3. Recurrent Pericarditis Disease Background and Overview
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Recurrent Pericarditis Incident cases 7MM
4.3. Recurrent Pericarditis 7MM Incident cases
4.4. Gender-specific Incidence of Recurrent Pericarditis (2016-2027)
4.5. Diagnosed and Treatable Cases of Recurrent Pericarditis (2016-2027)
4.6. Recurrent Pericarditis Country- Wise Epidemiology
4.7. United States
4.8. EU-5
4.9. Assumptions and Rationale
4.10. Germany
4.11. France
4.12. Italy
4.13. Spain
4.14. United Kingdom
4.15. Japan
5. Recurrent Pericarditis Treatments & Medical Practices
6. Recurrent Pericarditis Emerging Therapies
7. Key Cross Competition
7.1. Rilonacept: Kiniska Pharmaceuticals
8. Recurrent Pericarditis Market Size
9. 7MM Recurrent Pericarditis Country-Wise Market Analysis
10. United States Market Size
11. Germany Market Size
12. France Market Size
13. United Kingdom Market Size
14. Spain Market Size
15. Italy Market Size
16. Japan Market Size
17. Recurrent Pericarditis Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight